FDA
-
-
-
-
-
-
-
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
-
-
-
-
-
-
-
Pharvaris presents deucrictibant data at allergy conference
-
-
-
-
-
-
-
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
-
-
-
-
-
-
-
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
-
-
-
-
-
-
-
Pharvaris (PHVS) Outlines 2025 Strategic Priorities
-
-
-
-
-
-
-
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
-
-
-
-
-
-
-
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

